New Drug Discovery

Our drug discovery activities are channeled through two exclusive subsidiaries – Orchid Research Laboratories Limited in Chennai, India and Bexel Pharmaceuticals Inc., USA.

Orchid Research Laboratories Limited, Chennai (Orchid Research)

The wholly owned subsidiary, Orchid Research Laboratories Limited's ('Orchid Research'), multi-therapeutic, multi-lead portfolio and selective partnerships with the global customers for their projects reflects its emergence in the global drug discovery space as a potential player. Orchid Research stands out in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation, with faster decision making and execution excellence, re-enforcing its position as a preferred partner.

The centre comprises of independent laboratories for medicinal chemistry, analytical chemistry, molecular modeling, pharmacology & pharmacokinetics and molecular biology. Lead molecules have been identified in two therapeutic areas – anti-infectives and pain management – based on confirmatory microbiological and pharmacological studies. Pre-formulation and other studies are also in progress for further lead optimisation. Furthermore, our medicinal chemistry division has well trained scientists who perform design and synthesis of novel molecules in various therapeutic areas such as anti-infectives, anti-inflammatory, anti-cancer and metabolic disorders. They interact with the drug design group to synthesise second-generation patentable molecules that are either inspired by natural products or successfully marketed in these therapeutic areas.

Bexel Pharmaceuticals Inc., USA

Bexel Pharmaceuticals Inc. (Bexel), our drug discovery subsidiary in the USA, is working on – innovative compounds in the areas of diabetes, inflammation, obesity, multiple sclerosis, cardiovascular and auto-immune diseases. Bexel has progressed well on the development of an anti-diabetic lead (BLX-1002) with a unique anti-weight gain property. Orchid and Bexel Pharmaceuticals are engaged in a synergistic research endeavour that combines the chemistry, molecular modeling and pre-clinical capabilities of both institutions to yield a richer pipeline of potential new drugs.